|
Synonyms: AGEN-1181 | AGEN1181
Compound class:
Antibody
Comment: Botensilimab (AGEN-11810) is a Fc-enhanced anti-CTLA-4 monoclonal antibody [5]. It is proposed as an immuno-oncology agent for the treatment of poorly immunogenic and treatment refractory cancers [4,8]. Heavy and light chain peptide sequences for botensilimab are claimed in patent US10912831B1 [9], nominally SEQ IDs 25 and 27 respectively, and these are the chains of clone AGEN1884.H3 therein.
|
| Immunopharmacology Comments |
| CTLA-4 is an immune checkpoint protein. It is the target of anti-tumour immunotherapeutic agents known as immune checkpoint inhibitors, that are designed to promote tumour-reactive T-cell activation. Botensilimab selectively eliminates CTLA-4-expressing intratumoural regulatory T cells (Tregs) by binding more strongly to activating Fc-gamma receptors and inducing antibody-dependent cellular cytotoxicity/phagocytosis (ADCC/P) mechanisms [1,5]. |